This article is more than 5 years old. Information may no longer be current.

BioMimetic Therapeutics receives FDA filing letter for bone graft

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BioMimetic Therapeutics, Inc. announced in a press release that the U.S. Food & Drug Administration has accepted for review its Premarket Approval (PMA) application for Augment Bone Graft for use in foot and ankle fusions in the United States. The FDA has now filed the application and begun the comprehensive review of the clinical module, the company reported.

Following the submission of the PMA in February, FDA requested 12-month safety data for at least 85% of the Augment North American pivotal study patients in addition to the requirements previously set forth and agreed upon in the Investigational Device Exemption (IDE). In response to that request, in early May, the BioMimetic Therapeutics said it submitted 12 month data on 100% of the patient safety population, which demonstrate no new product related serious adverse events or any other safety concern.

Now that the FDA has officially accepted the application, the company anticipates receiving additional feedback from the agency in the third quarter, with an advisory panel review late this year or early 2011.

“Receipt of the PMA filing letter from the FDA is an important step in the process for approval of Augment Bone Graft in the U.S.,” Dr. Samuel Lynch, president and CEO of BioMimetic Therapeutics, stated in the release. “We expect to have the 100-day meeting with the FDA in the third quarter, at which time we will get more detailed feedback and questions from the agency related to the PMA application. We hope at that time to be able to agree with the Agency on a date for an advisory panel meeting for review of Augment.”